ESC Premium Access

New concepts in pulmonary hypertension

Event: ESC CONGRESS 2019
Topic: Treatment
Session type: Abstract Sessions
Date: 3 September 2019
Time: 08:30 - 10:00

Congress Session

6 presentations in this session

Validation of ESC/ERS 2015 guidelines risk score in patients with scleroderma associated pulmonary arterial hypertension (SSc-PAH)

Speaker: Doctor H. Fayed (London, GB)

Blood viscosity and its relevance to the diagnosis and management of pulmonary hypertension: a new elephant in the cathlab

Speaker: Doctor A. Kempny (London, GB)

Upfront triple combination therapy with ambrisentan, tadalafil and subcutaneous treprostinil in incident patients with severe pulmonary arterial hypertension

Speaker: Doctor M. D'Alto (Naples, IT)

Efficacy and safety of selexipag in pulmonary arterial hypertension (PAH) patients with and without significant cardiovascular (CV) comorbidities

Speaker: Professor S. Rosenkranz (Cologne, DE)

Waitlist outcomes for Eisenmengers patients listed for bilateral sequential lung transplant or heart-lung transplant

Speaker: Doctor K. Kearney (Sydney, AU)

Efficacy of pulmonary hypertension-targeted drugs for severe chronic thromboembolic pulmonary hypertension

Speaker: Doctor K. Takeuchi (Tokyo, JP)

6 speakers from this session

Doctor Hossam Fayed

University College London, London (United Kingdom of Great Britain & Northern Ireland)
1 presentation
0 follower

Doctor Aleksander Kempny

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)
0 follower

Doctor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)
3 presentations
0 follower

Professor Stephan Rosenkranz

Heart Center at the University of Cologne, Cologne (Germany)
20 presentations
0 follower

Doctor Katherine Kearney

St Vincents Hospital, Sydney (Australia)
0 follower

Doctor Kaori Takeuchi

, Tokyo (Japan)
0 follower

This platform is supported by

logo Novo Nordisk